Mirum Pharmaceuticals Secures $120 Million in Series A Financing to Develop Phase 3-Ready Maralixibat for Rare Liver Diseases

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2RHHsUm
via IFTTT